determined that RET regulates sensitivity of ER+ breast cancer cells to endocrine therapies and that activated RET promotes estrogen-independent activation of ERα (148), suggesting that RET and ERα pathway crosstalk in endocrine-resistant breast cancers. This evidence concerns the gene ESR1 and breast carcinoma.